LIBERTY, Mo., April 15, 2013 /PRNewswire/ — Antigen Laboratories, Inc., today announced that its parent company Planet Biopharmaceuticals, Inc. has signed a definitive agreement to be acquired by Ares Life Sciences (Ares), a healthcare focused investment group. Closing of the transaction is subject to certain closing conditions.

Theron E. Odlaug, Planet Executive Chairman and CEO, commented, “We are looking forward to becoming a member of the Ares portfolio of life science companies and the resources they will provide to help us continue to grow.”

About Antigen Laboratories, Inc.

Antigen Laboratories was founded in 1968 and has been providing quality allergenic extracts and ancillary supplies to the allergy profession for decades. For more information, visit www.antigenlab.com.

About Ares Life Sciences

Ares Life Sciences is a healthcare-focused investment group, whose financial backer is the Bertarelli family. Its strategy is to focus on key life sciences sectors, mainly: pharmaceuticals and biotechnology, medical diagnostics, and medical technology. Ares Life Sciences has a long-term view on investments and a core element of its investment strategy is to make available to its portfolio companies the collective experience and network of its team in the healthcare sector. Ares Life Sciences’ portfolio currently includes investments in Stallergenes, Euromedic, and Esaote.

Contact:
Planet Biopharmaceuticals, Inc.
Allen K. Roberson,
Vice President and CFO.
816-792-8512

SOURCE Planet Biopharmaceuticals, Inc.